All News
Treat-to-Target Strategy Cuts Mortality in Gout Patients
d
RheumNow
More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.
Read Article
RheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
Read Article
Amazing Single Center study using Methotrexate (~15/wk) prophylaxis in 10 pts starting IV pegloticase for refractory gout - ALL responded; no immunogenicity, no rise in SUA. Another way of preventing interference by anti-PEG Abs. #ACR18, Abstr #1286 https://t.co/D4oWLNYaPE
Links:
Dr. John Cush RheumNow ( View Tweet)
Remember cutaneous lupus can be caused by medication. This changes our treatment. https://t.co/UQZE65aOFk
Michele Meltzer Rheumforall ( View Tweet)
ACR18 Insights >>> Published by Sjögrens Forum in Twitter: RT @KDAO2011: My top 3 takehomes from #ACR18 are: @rheumnow 1. ACR is thinking about leaving ABIM & join ABAI to form a new board certifyin… https://t.co/92qBxCVC6h #ACR18 #LucidQuest #followthepatient https://t.co/S1YHIXgoAS
Links:
Dr Timos Papagatsias _timos_ ( View Tweet)
#Methotrexate and #leflunomide survival in #patients with #psoriatic #arthritis
Know more: https://t.co/kGlBeVFDzb https://t.co/1Nbq18Ai2O
Links:
Int J Clin Rheumatol rheumatol123 ( View Tweet)
Let's dig into today's announcement by @Potus & Dept of Health & Human Services to reduce #drugprices in Medicare Part B, from a rheumatology perspective. Read & retweet!
First: what was it? It's an Advance Notice of Proposed Rulemaking (ANPRM). Link:
https://t.co/ytxKpbElle
1/N
Angus Worthing MD AngusWorthing ( View Tweet)
This legitimately takes <1 min to do (see form in pic), and will help us avoid reimbursement cuts that would be disasterous for rheumatologists and our patiehts https://t.co/9FuirqGRod https://t.co/IxKeljB95O
Paul Sufka, MD psufka ( View Tweet)
New ACR guidelines for treatment management during pregnancy in patients with rheumatic diseases #ACR18 > AM https://t.co/RKhFHFJMt7
ARD & RMD Open ARD_BMJ ( View Tweet)
Patient safety is a critical part of Lilly's commitment to improving the rheumatoid arthritis treatment experience https://t.co/h4LD2oOOD3 #ACR18 https://t.co/ctXpr17Iar
Links:
Eli Lilly and Company LillyPad ( View Tweet)
It’s the psoriatic arthritis equivalent of watching Coltrane, Louis Armstrong and Duke Ellington on the same stage #ACR18 @RheumNow https://t.co/zGiJS6IDcS
David Liew drdavidliew ( View Tweet)
Comprehensive list of differential diagnosis of aortitis at vasculitis MOC session today. 1/3 of IgG4RD patients have vascular involvement (vasculitis+perivasc infiltrate) #ACR18 https://t.co/yu5ZO2dzCA
Didem Saygin, MD didemsayginmd ( View Tweet)
So proud of my dad for his hard work this year and his inspiring speech about the ACR's role in the future of medicine and politics! Also sincerely grateful for the opportunity to join in on so many of his trips and for always being so welcomed by the ACR. #ACR18 #Chicago https://t.co/fMQPLzMCcw
Clara Daikh CDaikh ( View Tweet)
In depth discussion on capillaroscopy by Dr. Cutolo. #ACR18 https://t.co/ni3HT94ue4
Lee Day UltrasoundRheum ( View Tweet)
Worth bearing in mind! #ACR18 https://t.co/07J8wj0j2C
Marco S Massarotti msmassarotti ( View Tweet)
1.Major political issues currently at stake for rheumatologists (eg CMS cuts for E/M service, step therapy) & need ⬆️ @ACRheum member help cc:@AngusWorthing
2.PEXIVAS: *negative* study on pheresis in severe AAV
3. Aggressive tx in MDA5+DM w/pred+CYC+tacro ⬆️survival
#ACR18 https://t.co/TX6muMR3nO
Paul Sufka, MD psufka ( View Tweet)
My top 3 takehomes from #ACR18 are: @rheumnow
1. ACR is thinking about leaving ABIM & join ABAI to form a new board certifying body: ABAIR
2.Don’t worry too much about 5mg/kg/d HCQ dose- Dr M Petri still uses 6.5 mg/kg/d
3. No sig ⬆️ risk CV/DVT/PE with tofa and baricitib https://t.co/3YNhYltnfW
k dao KDAO2011 ( View Tweet)
#ACR18 @RheumNow abs 837 high dose flu vaccine in RA pts 2-3 times more likely to seroconvert vs standard dose. No increase in RA disease activity. ? translates to less flu?
Ian N Bruce Lupusdoc ( View Tweet)
#ACR18 @RheumNow abs 838 MDA5 pos DM-ILD. Hi dose steroids + tac + IV CycloP had 85%survival at 12m vs 33% in historic controls. Note 31%also had PEx. 90%had CMV reactivation. Impressive nevertheless. #RareDisease
Ian N Bruce Lupusdoc ( View Tweet)
Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi
#biosimilars
Links:
Dr. John Cush RheumNow ( View Tweet)
